The story appears on

Page A2

July 5, 2013

GET this page in PDF

Free for subscribers

View shopping cart

Related News

Home » Nation

Drugs charges under the NDRC spotlight

CHINA'S top economic planner is to investigate 60 pharmaceutical companies, including several joint ventures with foreign firms, for excessive charges.

The National Development and Reform Commission will send teams to check wholesale prices and production costs at dozens of companies.

It said the companies include Sino-foreign joint ventures with Britain's GlaxoSmithKline, Germany's Boehringer-Ingelheim and global health care firm MSD.

The inquiry will also look at Chinese companies, among them industry leader Sinopharm Group and Jiangsu Hengrui Medicine.

Police are investigating senior GlaxoSmithKline staff in China for suspected "economic crimes" but it is unclear if there is any connection between the probes.

"There always has been a lot of pressure to make sure that common drugs are available at very cheap prices relative to what they would be sold for in a lot of Western markets," said Ben Cavender of the China Market Research Group consultancy.





 

Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.

沪公网安备 31010602000204号

Email this to your friend